HONG KONG -- A buying spree for new drugs developed by Chinese companies has sent Hong Kong-listed biotech shares nearly doubling in value this year, while a dozen biotech businesses have raised billions of dollars in the city under a special listing rule.
Biotechnology
China's biopharma boom echoes EV industry's success and stresses
Supply chain experience pays off but price competition and geopolitics loom
China's rise as a biopharmaceutical power has been more than a decade in the making, spurred on by an overhaul of drug approval regulations in 2015 and the inclusion of biotech as a strategic sector in the "Made in China 2025" initiative. (Source photos by AP)
Read Next
Latest on Biotechnology
